Evidence map›Paper›PMID 33262589›Full record

ReviewInternational journal of nanomedicine2020

Silver-Based Nanomaterials as Therapeutic Agents Against Coronaviruses: A Review.

Chanchal Das, Subha Sankar Paul, Arighna Saha, Tejinder Singh, Abhijit Saha, Jungkyun Im, Goutam Biswas

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Potential ofBioMed research international · 2022
    Pooled it
  2. Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022
    Article
  11. Article
  12. N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.Advances in pharmacological and pharmaceutical sciences · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chanchal DasDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal 736101, India.ORCID 0000-0002-9251-2104
Subha Sankar PaulSingapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 637551, Singapore.ORCID 0000-0002-4764-6314
Arighna SahaDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal 736101, India.
Tejinder SinghDepartment of Electronic Materials and Devices Engineering, Soonchunhyang University, Asan 31538, Republic of Korea.ORCID 0000-0002-4309-0232
Abhijit SahaChemistry Department, UGC-DAE Consortium for Scientific Research, Kolkata 700106, India.ORCID 0000-0002-0278-1600
Jungkyun ImDepartment of Electronic Materials and Devices Engineering, Soonchunhyang University, Asan 31538, Republic of Korea.ORCID 0000-0002-7926-5815
Goutam BiswasDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal 736101, India.ORCID 0000-0002-1488-2003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the identification of the first human coronavirus in the 1960s, a total of six coronaviruses that are known to affect humans have been identified: 229E, OC43, severe acute respiratory syndrome coronavirus (SARS-CoV), NL63, HKU1, and Middle East respiratory syndrome coronavirus (MERS-CoV). Presently, the human world is affected by a novel version of the coronavirus family known as SARS-CoV-2, which has an extremely high contagion rate. Although the infection fatality rate (IFR) of this rapidly spreading virus is not high (ranging from 0.00% to 1.54% across 51 different locations), the increasing number of infections and deaths has created a worldwide pandemic situation. To provide therapy to severely infected patients, instant therapeutic support is urgently needed and the repurposing of already approved drugs is presently in progress. In this regard, the development of nanoparticles as effective transporters for therapeutic drugs or as alternative medicines is highly encouraged and currently needed. The size range of the viruses is within 60-140 nm, which is slightly larger than the diameters of nanoparticles, making nanomaterials efficacious tools with antiviral properties. Silver-based nanomaterials (AgNMs) demonstrate antimicrobial and disinfectant effects mostly by generating reactive oxygen species (ROS) and are presently considered as a versatile tool for the treatment of COVID-19 patients. Other metal-based nanoparticles have been primarily reported as delivery agents or surface modifying agents, vaccine adjuvant against coronavirus. The present review summarizes and discusses the possible effectiveness of various surface-modified AgNMs against animal coronaviruses and presents a concept for AgNM-based therapeutic treatment of SARS-CoV-2 in the near future.

Indexed as

AnimalsAntiviral AgentsHumansNanostructuresSARS-CoV-2SilverAntiviral AgentsSilverantiviralcoronavirusSARS-CoVsilver nanocompositessilver nanomaterials

Identifiers

PMID33262589
PMCPMC7695609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.